Abstract: EP217609 is a new dual-action parenteral anticoagulant that combines an indirect factor Xa inhibitor (fondaparinux analogue) and a direct thrombin inhibitor (α-NAPAP analogue) in a single molecule together with a biotin tag to allow avidin neutralization.
EP217609 exhibits an unprecedented pharmacologic profile in showing high bioavailability, long plasma half-life and potent antithrombotic activity in animals without the complications of thrombin rebound. Here we report the exceptional specificity and selectivity profile of EP217609. EP217609 inhibited thrombin with rapid kinetics (k on >10 7 M -1 s -1 ), a high affinity (K I 30-40 pM) and >1000-fold selectivity over other coagulation and fibrinolytic protease targets, comparing favorably with the best direct thrombin inhibitors known. EP217609 bound antithrombin with high affinity (K D 30 nM) and activated the serpin to rapidly (k ass ~10 6 M -1 s -1 ) and selectively (>20-fold) inhibit factor Xa. The dual inhibitor moieties of EP217609 acted largely independently with only modest linkage effects of ligand occupancy of one inhibitor moiety on the potency of the other (~5-fold). In contrast, avidin binding effectively neutralized the potency of both inhibitor moieties (20-100-fold). These findings demonstrate the superior anticoagulant efficacy and rapid avidin neutralizability of EP217609 compared to anticoagulants that target thrombin or factor Xa alone.
For personal use only. on September 14, 2017 . by guest www.bloodjournal.org From Heparin has been the reference anticoagulant drug of choice for the prevention and treatment of venous thrombosis for the past 70 years 1 . The anticoagulant activity of this natural glycosaminoglycan derives from a specific pentasaccharide sequence that binds and activates the plasma serpin inhibitor of blood coagulation proteases, antithrombin 2, 3 . However, numerous offtarget interactions of heparin with other plasma proteins and cells compromise the effectiveness and safety of this anticoagulant. Such interactions result in variable dosage requirements and consequent risks of bleeding, the danger of eliciting the immune syndrome, heparin-induced thrombocytopenia (HIT) and problems with thrombin rebound following anticoagulant therapy 1, [4] [5] [6] [7] . The heparin pentasaccharide mimetics, fondaparinux and idraparinux, were developed to eliminate such off-target interactions and have been shown to be specific antithrombin-mediated inhibitors of factor Xa with predictable pharmacokinetic profiles and no risk of HIT [8] [9] [10] [11] . However, problems with thrombin-rebound remain with these mimetics which appear to result from the inability to inhibit clot-bound thrombin. 12 The predictable pharmacokinetics of fondaparinux was the impetus for developing a dual factor Xa and thrombin inhibitor that combines a fondaparinux-like antithrombin-mediated inhibitor of factor Xa with an α -NAPAP-like direct thrombin inhibitor [13] [14] [15] [16] . The first compound of this generation, EP42675 ( Fig. 1) , inhibits free and clot-bound thrombin in a manner like that of the related direct reversible thrombin inhibitor, and retains the anti-factor Xa activity, complete bioavailability, long half-life and predictable pharmacokinetic properties of fondaparinux. Moreover, it shows a strong antithrombotic activity in both arterial and venous thrombosis models and no evidence of rethrombosis in an experimental thrombolysis model 17 .
Addition of a biotin tag to the structure of EP42675 yielded EP217609 ( Fig. 1 ) that retained the anti-IIa and anti-factor Xa activities and pharmacokinetics of EP42675 and could be rapidly
For personal use only. on September 14, 2017 . by guest www.bloodjournal.org From neutralized by avidin injection 15 . In man, administration of avidin triggered a rapid and irreversible neutralization of EP217609 without rebound effect 18 .
EP217609 is currently under investigation in a phase II clinical trial as a reversible anticoagulant in cardiopulmonary bypass (CBP) surgery. Surprisingly, the current standard of care for anticoagulation in CPB remains heparin and its neutralizing agent protamine, as safer or more efficacious anticoagulants have yet to be found 19 . Low molecular weight heparin or the heparin-like danaparoid have been used in CPB but they produce inadequate thrombin inhibition and are not neutralized by protamine 20,21 . The direct thrombin inhibitors bivalirudin and argatroban, have also been tested in patients but none of these agents represents a real alternative to the heparin-protamine couple 22,23 . A new approach based on the use of a reversible selective factor IXa inhibitor is promising but has not been tested in man 24 .
While EP217609 shows a promising pharmacologic profile, quantitative biochemical studies of the potency and selectivity of the dual inhibitor for its targets have not been done to provide a biochemical foundation for understanding its exceptional pharmacologic efficacy. Here we demonstrate that EP217609 is among the highest affinity (K I 30-40 pM) and selective (>1000fold) direct thrombin inhibitors known and is a rapid (k ass~1 0 6 M -1 s -1 ) and selective (>20-fold) antithrombin-mediated inhibitor of factor Xa. Avidin binding directly neutralizes the dual inhibitor activities in addition to the indirect neutralization that results from accelerated clearance of the drug. Our findings support the promise of EP217609 as a next generation anticoagulant capable of reversible inhibition of both existing and newly generated thrombin. Current phase 2 clinical trials evaluating EP217609 anticoagulant efficacy in CPB will provide an important test of this promise.
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Materials and Methods
Materials-Proteases of human origin were from Enzyme Research Laboratories and their concentrations determined by active-site titrations, as in prior studies 25 . Human antithrombin was purified from blood plasma as described 26 . Concentrations of the protein were determined from the absorbance at 280 nm using an extinction coefficient of 37,700 M -1 cm -1 . 27 The recombinant extracellular domain of human tissue factor was a gift of the late Dr. Yale Nemerson. Egg white avidin was provided by Endotis Pharma. The concentration of avidin solutions was determined by HPLC comparing the area under the curve with that of a standard of known concentration. All proteins were judged pure by SDS-PAGE analysis 28 . Synthetic p-nitroanilide chromogenic and 7-amido-4-methylcoumarin (AMC) fluorogenic protease substrates were purchased from Chromogenix, American Diagnostica, Centerchem or Sigma. Substrate concentrations were determined by absorbance using published extinction coefficients 25 . The heparin pentasaccharide mimetics, fondaparinux and idraparinux 8, 9 , were provided by Sanofi-Aventis and their concentration determined by weight from the molecular weight. Endotis Pharma (EP) compounds were provided as aqueous solutions whose molar concentrations were determined by NMR spectroscopy using an internal standard.
Experimental conditions-All experiments except where otherwise noted were performed at 25 o C in an I 0.15 buffer consisting of 100 mM Hepes, 93.5 mM NaCl, 5 mM CaCl 2 , 0.1% PEG 8000, pH 7.4.
Binding of EP compounds to antithrombin and thrombin-Stoichiometries and dissociation
constants for the binding of EP compounds to antithrombin were measured by fluorescence titrations as in past studies 26 . Stepwise additions of compounds to antithrombin were made followed by monitoring the increases in protein fluorescence that signal binding of the heparin 26 For stoichiometric titrations, K D was fixed based on the ionic strength dependence of K D measured for fondaparinux 10 , and the maximal fluorescence change and the stoichiometric factor were fit as adjustable parameters. The fitted stoichiometric factor was assumed in titrations to determine binding affinity, in which case K D and the maximal fluorescence change were the fitted parameters.
Binding of the EP compounds to thrombin was measured by fluorescence titrations in the presence of the probe, p-aminobenzamidine 26 , by following the decrease in fluorescence at 370 nm (λ ex 330 nm) due to the displacement of bound p-aminobenzamidine from the thrombin active-site that accompanies compound binding. Fluorescence changes were fit by the quadratic equilibrium binding equation. The K D for the thrombin-EP compound interaction in these fits was fixed at the measured K I value 26 . The maximal fluorescence change and stoichiometric factor were the fitted parameters. where v o is the initial velocity of substrate hydrolysis in the absence of inhibitor and K I * is the apparent dissociation constant for inhibitor binding 29 . K I * is related to K I by a factor that accounts for the competitive effect of substrate binding: where [E] o is the total protease concentration, n is a stoichiometric factor and all other parameters are as indicated in the hyperbolic equation above 29 . The fitted parameters were v o , n, and K I *. It should be noted that under conditions where inhibitor dissociation from the protease is slow relative to the time over which substrate hydrolysis is measured, the substrate will only interact with the free protease and not compete with the inhibitor-bound protease and therefore K I * will be equal to K I .
Measurements of K I values for protease inhibition by the EP compounds-
K I * = K I x (1 + [S] o /K M ) where [S] o
Kinetics of protease reactions with antithrombin-EP compound complexes-Kinetic studies of the reactions of antithrombin-EP compound complexes or antithrombin-idraparinux complex with
proteases were performed similar to previous studies 25 . Idraparinux was chosen as a reference because of its high-affinity for antithrombin and because it activates antithrombin identical to fondaparinux. 25 EP compound or idraparinux concentrations were in 1.5-fold molar excess over the antithrombin concentration except for reactions of proteases that bound the α -NAPAP-like unit of the EP compounds with submicromolar K I values in which case the EP compound was equimolar with or lower than the antithrombin concentration to minimize competitive inhibition by the free EP compound. In all cases, the protease concentration was at least 10-fold lower than the concentration of antithrombin-EP compound complex to ensure pseudo-first order reaction conditions. Reactions were initiated by adding protease to antithrombin and EP compound or Linkage effects-The effect of antithrombin binding to the EP compound on the K I for thrombin binding was analyzed according to the linkage scheme and equation:
where K I,app is the apparent K I measured in the absence or presence of antithrombin, [AT] o is the total antithrombin concentration, and K EP,T , K EP-T,AT , and K EP-AT,T are dissociation constants for thrombin binding to free EP, for antithrombin binding to the binary EP-thrombin complex, and for thrombin binding to the binary EP-antithrombin complex, respectively. K EP-T,AT was determined by comparing the kinetics of factor Xa inhibition by antithrombin complexes with free EP versus EP-thrombin binary complex based on the equation:
where k obs,-T /k obs,+T is the ratio of observed pseudo-first order rate constants for reactions of antithrombin complexes with free EP and EP-thrombin binary complex and K EP,AT is the dissociation constant for antithrombin binding to free EP. The measured values of K I,app , K EP,T , and K EP-T,AT , were then used to calculate K EP-AT,T from the linkage equation.
Results

EP compounds bind tightly to antithrombin and thrombin -The ability of the EP compounds to
bind both antithrombin and thrombin with high affinity was initially assessed by equilibrium binding titrations. Titrations of antithrombin with EP42675 and its biotin conjugate, EP217609 ( Fig. 1) , were monitored by changes in the tryptophan fluorescence of antithrombin that report binding of the fondaparinux-like moiety of the compounds 10 . At low ionic strength, the EP compounds produced identical linear increases in fluorescence up to an endpoint corresponding to a ~40% fluorescence enhancement after ~1 mole of compound/mole antithrombin had been added ( Fig. 2A ), indicating stoichiometric binding of the compounds to the serpin. Titrations at physiologic ionic strength resulted in more gradual hyperbolic increases in fluorescence with increasing additions of the two compounds that indistinguishably approached saturable endpoints equivalent to those observed at low ionic strength. Fitting of the latter titrations by the equilibrium binding equation indicated identical K D s of 30-32 nM, representing binding affinities ~2-fold stronger than fondaparinux (K D 60 nM), but ~60-fold weaker than the mimetic, idraparinux (K D 0.4 nM), which has an additional two sulfates 9, 32 (Table 1 ). The measured K I for binding of the nonbiotinylated EP42675 to thrombin was 61±20 pM ( Table 2 ). The biotin label of EP217609 increased the affinity to 43±16 pM, although the significance of these differences was marginal due to the large errors in KI at the protease concentration employed (~20 x KI). Titrations performed at a 10-fold lower thrombin concentration confirmed the KI values measured at higher thrombin concentration and the modestly higher affinity of thrombin for the biotin-labeled than the unlabeled compound ( The substrate hydrolysis activity of five other proteases was inhibited by the EP compounds over the range of inhibitor concentrations examined (Fig. 3 ). Because inhibitor concentrations greatly exceeded protease concentrations in these titrations, inhibition of each of the proteases was well fit by the equation for simple hyperbolic competitive inhibition.
Corrections of apparent inhibition constants for substrate binding were applied in each case. Two proteases, factor XIa and activated protein C (aPC), bound the EP compounds with moderately high affinities ( No significant inhibition by the EP compounds was observed for several of the proteases up to 10 -5 M compound, including factor IXa, factor VIIa-tissue factor complex, factor XIIa and tPA ( Fig. 3) . K I values for EP compound binding to these proteases were thus estimated to greatly exceed 10 μM (Table 2) .
Antithrombin-EP compound complexes selectively inhibit factor Xa-Progress curves for the inhibition of the enzymatic activity of the procoagulant and anticoagulant proteases by antithrombin complexes with EP compounds and with the reference compound, idraparinux,
were compared under the same conditions as K I determinations and under pseudo-first order reaction conditions. Observed pseudo-first order rate constants (k obs ) for the inhibition reactions were proportional to the antithrombin-EP compound complex concentration in all cases, providing the second-order rate constants (k ass ) in Table 3 . k ass values were experimentally indistinguishable for reactions of any protease with antithrombin complexed with either
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From EP42675 or EP217609, indicating no effect of the biotin tag. Comparison of k ass values for all protease reactions showed that antithrombin-EP complexes preferentially inhibited factor Xa with a pharmacologically significant rate constant of ~10 6 M -1 s -1 and with >20-fold selectivity over other proteases. This protease reaction profile resembled that of the antithrombinidraparinux complex except for proteases that were directly inhibited by the α -NAPAP-like part of the EP compound. The proteases that bound the α -NAPAP-like moiety with the highest affinity, thrombin, aPC and factor XIa, showed either no detectable antithrombin-mediated inhibition by the EP compounds or a significantly reduced rate of inhibition relative to reactions with the antithrombin-idraparinux complex. This was fully accounted for by competitive inhibition of the antithrombin-mediated reaction by the α -NAPAP-like part of the EP compounds. Such competitive effects thus amplified the selectivity of the antithrombin-EP complex for inhibiting factor Xa relative to these proteases.
Stereoisomeric configuration of EP217609 is unimportant for direct and antithrombin-mediated
inhibition of proteases-Because the biotin tag of EP217609 is attached at a chiral carbon, the compound consists of a mixture of two diastereoisomers, EP217609-1 and EP307138-1 (Fig. 1 ).
K I values and second order rate constants for direct and antithrombin-mediated inhibition of proteases by the separate stereoisomers were therefore measured. The configuration of the biotin tag had minimal effect on the K D for binding of the stereoisomers to antithrombin ( showed little or no significant differences between the stereoisomers for any of the proteases except for factor XIa ( Table 3 ). The latter were accounted for by differential competitive inhibition by the direct inhibitor parts of the compounds.
Linkage effects on inhibitor potency-Since at plasma concentrations of antithrombin (2-3 μM),
EP217609 is expected to be fully complexed with the serpin given the measured K D for this interaction, it was important to determine how antithrombin binding to the fondaparinux-like unit of the compound affects the binding of the α -NAPAP-like unit to proteases. This was assessed for the three proteases that bound the inhibitor with the highest affinity, namely thrombin, aPC and factor XIa. Comparison of titrations of these proteases with the EP compounds in the absence and presence of antithrombin levels that caused minimal antithrombin-mediated inhibition over the time of measurement, showed that the serpin reduced the affinity of the EP compounds for the proteases from ~2-fold for thrombin at 0.1 μM antithrombin to 5-7-fold for aPC and factor XIa at 0.5-1 μM serpin (Fig. 5A ).
To validate that the observed linkage of antithrombin binding and protease binding to the EP compounds was reciprocal, we evaluated the effect of thrombin at levels equimolar with EP42675 or EP217609 on the inhibition of factor Xa by the antithrombin-EP binary complex ( Fig. 5B) . A modest, but highly reproducible ~30% decrease in the exponential rate constant for factor Xa inhibition was observed for both EP compounds in the presence of equimolar thrombin. Assuming that this decrease reflects a reduced affinity of the EP compound for antithrombin, we calculated an affinity loss of ~5-fold (K D 150 nM) (see Methods). This loss in antithrombin affinity suggested that the ~2-fold decrease in EP affinity for thrombin observed at 100 nM antithrombin underestimated the maximal affinity loss at saturating antithrombin.
Calculation of the maximal affinity decrease from the linkage equation given in Methods
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From indicated a ~5-fold loss in affinity of EP for thrombin at saturating levels of antithrombin, a value comparable to the loss in affinity observed with aPC and factor XIa at near saturating antithrombin levels. The reciprocal ~5-fold effects of thrombin binding on antithrombin binding and vice versa are consistent with the two interactions being thermodynamically linked. Notably, the linkage is modest, antithrombin binding to EP217609 still resulting in strong direct thrombin inhibition (K I ~200 pM) and thrombin binding minimally affecting the binding of antithrombin at plasma antithrombin concentrations (reduction from 99% to 93%).
Avidin effectively neutralizes the dual inhibitor moieties of EP217609 -EP217609 contains a
biotin tag that allows neutralization of the compound in vivo upon avidin administration through accelerated clearance. To determine whether avidin binding directly affected the compound's dual inhibitor activities, we compared EP217609 inhibition of thrombin and factor Xa in the absence and presence of a 1-2-fold molar excess of avidin. Avidin markedly weakened the direct inhibitory effect of EP217609 on thrombin, the K I increasing 100-fold from 43±16 pM to 4.4±0.3 nM (Fig. 6) . Avidin had no effect on the K I for thrombin inhibition by the nonbiotinylated EP42675. The observation that the apparent K I measured in the presence of avidin was unaffected by doubling the substrate concentration indicated that no correction of this K I for substrate competition was necessary. This implied that avidin weakened the K I not by increasing k off , but instead by decreasing k on .
Avidin reduced k obs for EP217609-antithrombin complex inhibition of factor Xa by ~5fold, but had no effect on EP42675-antithrombin complex inhibition (Fig. 7A ). To verify that this was due to a reduced affinity of antithrombin for the EP217609-avidin complex, we performed kinetic titrations of antithrombin with free and avidin-complexed EP217609 under conditions where saturable increases in k obs for antithrombin inhibition of factor Xa provided the For personal use only. on September 14, 2017. by guest www.bloodjournal.org From K D for EP compound binding to antithrombin as well as the maximal rate constant associated with full activation of the serpin (Fig. 7B) 34 . Avidin substantially weakened the binding of EP217609 to antithrombin without affecting the maximal activation. The K D s obtained in the absence and presence of avidin equimolar with the highest EP compound concentration assuming equivalent endpoints were 44±6 nM and 1040±50 nM, respectively, indicating that avidin produces a 20-30-fold reduction in EP217609 affinity for antithrombin. The observed ~5-fold reduction in the apparent EP-accelerated rate constant but ~20-30-fold reduction in EP affinity for antithrombin is a consequence of the antithrombin concentration used to measure the rate constant exceeding the K D for EP compound binding in the absence of avidin but being well below K D in the presence of avidin. When the apparent rate constants measured are corrected for the increase in K D caused by avidin, equivalent second order rate constants of 7.6±1.2 x 10 5 M -1 s -1 and 7.7±0.9 x 10 5 M -1 s -1 for the antithrombin-EP217609 complex reaction with factor Xa in the absence and presence of avidin, respectively, were obtained.
Discussion
Previous reports have documented the potent anti-IIa and anti-factor Xa activities of EP217609 and its nonbiotinylated counterpart EP42675 in plasma, as well as the favorable pharmacokinetic properties, sustained antithrombotic activity and avidin-mediated neutralization of EP217609 in vivo 15, 17 . In the present study, we have performed a comprehensive biochemical characterization of EP217609 and EP42675 potency and selectivity to provide new mechanistic insights into the potent antithrombotic activity of EP217609. Our results show that the inhibitors possess a high degree of specificity for their targets, (K I 30-60 pM for thrombin and k ass 6-7 x 10 5 M -1 s -1 for factor Xa) as well as a marked selectivity for these proteases (K I >1000-fold greater and k ass >20-fold slower for all other coagulation and fibrinolytic proteases tested). The
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From biotin tag was found to minimally perturb the specificity and selectivity toward the dual targets in either of its stereoisomeric configurations, thereby providing a nonperturbing means for neutralizing the compound's activity with avidin. Notably, avidin binding to EP217609 was found to cause a large loss in inhibitor potency (100-fold increase in K I for thrombin and 20-30fold increase in the K D for antithrombin binding), contributing to an immediate neutralization of the drug's activity in addition to the indirect neutralization caused by avidin accelerating its clearance 15, 35 . Phase I clinical studies in man have indeed shown that administration of avidin triggers a rapid and irreversible neutralization of EP217609 without rebound effect. 18 The selectivity of EP217609 as a direct thrombin inhibitor largely derives from the extremely high affinity of the α -NAPAP-like moiety for thrombin (K I 30-40 pM) that ranks among the highest affinity direct thrombin inhibitors known 6, 36 . This affinity is much greater than that of α -NAPAP or related inhibitors such as argatroban 37 , the result of structure-activity optimization that included replacement of the naphthylsulfonamide moiety and incorporation of the active stereoisomer of the amidinophenyl substituent 14 . The kinetics of inhibition are rapid and conform to a simple one-step reversible equilibrium with no evidence for any induced-fit slow binding step. The protease with the next highest affinity, aPC, was inhibited with a K I value of ~10 -7 M, that was 1000-fold higher than that for thrombin. Factor XIa was inhibited with an even higher K I approaching micromolar and all other proteases were inhibited with K I values exceeding 10 -6 M. This selectivity parallels that previously reported for other α -NAPAP analogues, although those with considerably reduced specificity for thrombin 36 . The biotin tag somewhat enhanced the affinity for all proteases except aPC, thereby contributing to the high selectivity of EP217609 for thrombin over aPC. Since EP217609 is expected to act pharmacologically with antithrombin bound, it was important to find that antithrombin binding only modestly decreased the affinity of EP217609 for thrombin without affecting the selectivity for thrombin over aPC. Therapeutic doses of EP217609 are thus not expected to significantly perturb the anticoagulant function of aPC.
EP217609 and the nonbiotinylated EP42675 were found to act like the natural heparin pentasaccharide, fondaparinux, or its higher affinity mimetic, idraparinux, in transforming antithrombin into a highly selective factor Xa inhibitor 25 . Thus, comparison of the relative values of k ass for reaction of proteases with antithrombin complexed with any of the EP compounds showed that EP compound activation of antithrombin, as with fondaparinux or idraparinux activation, alters the specificity profile of antithrombin to favor inhibition of factor Xa over all other proteases. Factor Xa is thus inhibited by the antithrombin-EP compound complex with a rapid rate constant of ~10 6 M -1 s -1 whereas all other coagulation and fibrinolytic proteases whose inhibition rate could be measured are inhibited 20-50,000-fold slower than factor Xa.
Importantly, the two inhibitor moieties of EP217609 were found to act in a largely independent manner with relatively modest ~5-fold linkage effects of the binding of one protein on the binding of the other. Either inhibitor moiety thus retains a high potency irrespective of whether the other moiety is bound to its protein ligand. The flexible spacer unit that separates the two inhibitor moieties thus allows each inhibitor to act independently. By contrast placement of the biotin tag at the junction between the two inhibitor moieties results in a larger effect of avidin binding on the inhibitor interactions with their protein ligands.
The present report together with prior reports shows that the strategy of combining two separate inhibitor moieties with distinct mechanisms of action yields an anticoagulant with unprecedented pharmacological properties. Thus, the predictable pharmacokinetic properties of the fondaparinux analogue are transferred to a direct thrombin inhibitor, making EP217609 a
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From unique anticoagulant. Its potent antithrombotic activity in both venous and arterial thrombosis models is in part related to its ability, shared with other direct thrombin inhibitors, to inactivate clot bound thrombin as well as free thrombin. Importantly, its long half-life, predictable pharmacokinetics and neutralizability cannot be replicated by co-administration of the individual inhibitor compounds. EP217609 thus shows great promise in overcoming the limitations of current anticoagulants, and the EP217609-avidin couple represents an attractive anticoagulation system for cardiopulmonary bypass. Ongoing clinical trials will tell if this new system offers a better benefit/risk ratio than the heparin-protamine system that has been used for over 60 years in this indication. 5.0±0.9 For personal use only. on September 14, 2017. by guest www.bloodjournal.org From The indirect factor Xa inhibitor moiety (fondaparinux analogue), direct thrombin inhibitor moiety and biotin label of EP217609 are indicated. The biotin is attached to the linker between the two inhibitor moieties through a lysine spacer indicated by the arrow. EP217609 is a mixture of diastereomers containing either an L-lysine spacer (EP217609-1) or a D-lysine spacer (EP307138-1). EP42675 lacks the lysyl-biotinyl group indicated by a box. Data for EP217609 only is presented for the four proteases whose activity was insignificantly inhibited over the same EP compound concentration range. Solid and dashed lines are fits of EP217609 and EP42675 data, respectively, by equations for tight binding or regular competitive inhibition which yielded values of K I *. K I was calculated from K I * by dividing the latter by the factor for competitive substrate inhibition except for the K I * measured for thrombin which required no correction. K I values are tabulated in Table 2 . antithrombin, respectively. Values of K I * obtained from fits were corrected for competitive substrate binding for aPC and factor XIa. B, Progressive inhibition of factor Xa by increasing concentrations of antithrombin-EP42675 (triangles) and -EP217609 (circles) complexes was measured in the absence (open symbols) and presence (closed symbols) of thrombin levels equimolar with EP compound for reactions containing 200 nM antithrombin, 0.5 nM factor Xa and the indicated EP concentrations for a fixed reaction time of 300 s. Inverted triangles are controls in which antithrombin was omitted from factor Xa reactions with equimolar EP42675 and thrombin. Solid lines are fits by a single exponential decay function which yielded k obs values. These were used to calculate the dissociation constant for antithrombin binding to the EP-thrombin binary complex as described in Methods. : Effect of avidin on EP217609-accelerated antithrombin inhibition of factor Xa-A, EP217609-accelerated antithrombin inhibition of factor Xa activity is shown as a function of EP217609 concentration in the absence and presence of avidin. Reactions contained 200 nM antithrombin, 5 nM factor Xa, the indicated EP compound concentration and 0 (•), 12 nM (▲) or 24 nM ( ) avidin as indicated for a fixed reaction time of 300 s. Solid lines are fits by a single exponential function from which k obs was obtained. B, Kinetic titrations of the binding of EP217609 to 50 nM antithrombin in the absence (•) and presence (▲) of 1000 nM avidin followed from the enhancement by the EP compound of the rate of antithrombin inhibition of 5 nM factor Xa. Plotted are observed pseudo-first order rate constants (k obs ) calculated from the extent of antithrombin inhibition of factor Xa in the presence of the indicated concentrations of EP217609 in the absence or presence of avidin for 1 minute reactions. Solid lines are fits to the quadratic binding equation from which K D for the antithrombin-EP217609 interaction and the maximal rate constant for the antithrombin-EP217609 reaction with factor Xa were obtained. It should be noted that reciprocal effects of antithrombin binding on avidin binding are insignificant because avidin binds biotin with a femtomolar K D .
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